LUMBY, British Columbia, Oct. 16 /PRNewswire-FirstCall/ -- AVVAA World Health Care Products, Inc. (BULLETIN BOARD: AVVW) , a biotech company offering global customers therapeutic skin and health care products, is pleased to announce it has filed its SEC form 10-QSB quarterly report containing financial and operating results for the three months ended August 31, 2006.
AVVAA reports a loss for the three months ended August 31, 2006 of $1,419,377, or $0.02 per share, as compared to a loss of $799,056 or $.02 per share, for the comparable three months ended August 31, 2005. These loss per share numbers are based on the number of shares outstanding at their respective time frames.
AVVAA World Health Care Products CEO and Chairman Jack Farley said, "We have had a number of substantial developments in the recent quarter that should result in success for our products in the marketplace. Recent, large-scale advertising and marketing campaigns have broadened brand awareness and increased customer recognition, while adding sales in target markets. In addition, substantial new in-roads were forged by avVaa's top-notch sales team -- especially for our popular pet and equine products, that are now selling throughout Canada and the U.S."
"For the year, we expect to continue to benefit from existing campaigns as we implement a number of planned initiatives to ensure long-term successes for the Company and its growing line of unique skin-care products that meet the needs of thousands of consumers. Our plan is to issue a shareholder letter in the very near future to update shareholders more specifically on the progress of the company."
This press release briefly summarizes only certain portions of the Company's Quarterly Report on Form 10-QSB for the three months ended for August 31, 2006 and readers should review the entire report filed with the SEC and available at http://www.sec.gov/.
About avVaa World Health Care Products
avVaa World Health Care Products (AVVW) is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass, food and drug channels in the United States and globally.
For additional information on avVaa contact Jack Farley CEO / Chairman, at 1-866-772-8822 or visit: http://www.avvaa.com/ or http://www.otcfn.com/avvw
Investor Relations: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349; or Geoffrey Eiten of OTC Financial Network, 1-781-444-6100 ext. 613
Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of AVVAA World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
